	Application No.	Applicant(s)
Notice of Allowability	09/246,307	KOZIKOWSKI ET AL.
	Examiner	Art Unit
	Anish Gupta	1654
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>7-31-06</u> .		
2. The allowed claim(s) is/are <u>12,14-17,21,23-28,31,32 and 74-95</u> .		
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
·		
Attachment(s)	5 Motion of Informal D	Patent Application
1. Notice of References Cited (PTO-892)	5. ☐ Notice of Informal P 6. ☐ Interview Summary	• •
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	Paper No./Mail Dat	te
3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 11-7-05	7. 🛛 Examiner's Amendr	nent/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material		ent of Reasons for Allowance
ANISH GUPTA PRIMARY EXAMINER	9.	

Application/Control Number: 09/246,307

Art Unit: 1654

DETAILED ACTION

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

On page 1, after the heading "CROSS REFERENCE TO RELATED APPLICATIONS," the following has been added:

This application is a continuation-in-part of application Serial No. 09/022,184, filed February 11, 1998, now abandoned, and a continuation-in-part of provisional application Serial No. 60/095,788, filed August 7, 1998. The contents of both of these applications are hereby incorporated herein by reference in their entireties.

2. The following is an examiner's statement of reasons for allowance:

The claims are drawn to a method of providing neuroprotection to a subject resulting form either brain or spinal cord trauma or stroke comprising administering a compound of the formula:

The prior art of Bowen et al. (US5679679) discloses compounds that are effective in

Page 3

Application/Control Number: 09/246,307

Art Unit: 1654

the treatment of CNS disorders. The reference further discloses compounds that have the structural attributes of the claimed compounds. However, the compounds corresponding to the compounds of the formula claimed are utilized by the prior art as intermediates to produce structurally distinct compounds, from those claimed in the instant application, which are used in the treatment of CNS disorders (see col. 13-14 as examples). The prior art does not teach nor suggest that these intermediates themselves are effective in the treatment of CNS disorders. Thus, the prior art does not teach nor suggest the claimed invention. Thus, the claimed invention is both novel and unobvious.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anish Gupta whose telephone number is (571)272-0965. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can normally be reached on (571) 272-0562. The fax phone number of this group is (571)-273-8300.

Anish Gupta) Patent Examiner